-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FfwFGFOadMiMt/f6Vp/Pn8gXHArd88418RsWkZdtwxU/PEO0/Kj9+Xqyv2UohCJ9 SFag09vqh02YoQ0E/20jEg== 0001264124-05-000172.txt : 20050611 0001264124-05-000172.hdr.sgml : 20050611 20050526190249 ACCESSION NUMBER: 0001264124-05-000172 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20050525 FILED AS OF DATE: 20050526 DATE AS OF CHANGE: 20050526 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMYLIN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000881464 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330266089 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6195522200 MAIL ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WILSON JAMES N CENTRAL INDEX KEY: 0001236387 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19700 FILM NUMBER: 05861301 BUSINESS ADDRESS: BUSINESS PHONE: 8585522200 MAIL ADDRESS: STREET 1: AMYLIN PHARMACEUTICALS INC STREET 2: 9360 TOWNE CENTRE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgardoc.xml PRIMARY DOCUMENT X0202 4 2005-05-25 0 0000881464 AMYLIN PHARMACEUTICALS INC AMLN 0001236387 WILSON JAMES N 9360 TOWNE CENTRE DR SAN DIEGO CA 92121 1 0 0 0 Non-Qualified Stock Option (right to buy) 16.23 2005-05-25 4 J 0 12000 0 A 2005-05-25 2015-05-25 Common Stock 12000 12000 D By: /s/ Darin M. Lippoldt, Attorney-in-Fact For: James N. Wilson 2005-05-26 EX-24 2 wilsonpoa.txt EDGAR SUPPORTING DOCUMENT POWER OF ATTORNEY Known all by these presents, that the undersigned hereby authorizes Ginger L. Graham, Daniel M. Bradbury, Lloyd A. Rowland, Mark G. Foletta or Darin M. Lippoldt to execute for and on behalf of the undersigned, in the undersigned's capacity as a Director of Amylin Pharmaceuticals, Inc. (the "Company"), Forms 3, 4 and 5 of any Amendments thereto, and cause such form(s) to be filed with the Securities and Exchange Commission pursuant to Section 16(a) of the Securities Exchange Act of 1934, relating to the undersigned's beneficial ownership of securities in the Company. The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or substitute or substitutes of such attorney-in-fact, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of, and transactions in, securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed this 24th day of May, 2005. /s/ James N. Wilson James N. Wilson -----END PRIVACY-ENHANCED MESSAGE-----